Avanos Medical (NYSE:AVNS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Avanos Medical (NYSE:AVNS) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

Other research analysts have also issued research reports about the stock. Zacks Research raised shares of Avanos Medical to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research note on Tuesday, October 14th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Avanos Medical Trading Up 1.9%

Shares of AVNS stock opened at $11.44 on Friday. Avanos Medical has a 12 month low of $9.30 and a 12 month high of $21.12. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $11.67 and its two-hundred day moving average is $11.90. The company has a market cap of $531.04 million, a PE ratio of -1.12 and a beta of 1.19.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.10. The business had revenue of $177.80 million during the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. Avanos Medical’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Equities analysts predict that Avanos Medical will post 1.32 EPS for the current year.

Insider Transactions at Avanos Medical

In other news, Director Gary Blackford purchased 40,000 shares of the business’s stock in a transaction on Wednesday, August 13th. The stock was purchased at an average price of $10.99 per share, with a total value of $439,600.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $439,600. The trade was a ? increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 2.64% of the stock is owned by corporate insiders.

Institutional Trading of Avanos Medical

Several institutional investors have recently modified their holdings of AVNS. Principal Financial Group Inc. increased its holdings in Avanos Medical by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 244,063 shares of the company’s stock valued at $3,497,000 after buying an additional 6,269 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Avanos Medical during the 2nd quarter worth about $192,000. T. Rowe Price Investment Management Inc. boosted its position in shares of Avanos Medical by 24.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company’s stock valued at $53,847,000 after acquiring an additional 746,264 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Avanos Medical during the 2nd quarter valued at about $262,000. Finally, Nuveen LLC bought a new stake in Avanos Medical in the first quarter valued at about $1,839,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.